Serum levels of antimicrobial peptides in children with atopic dermatitis
Abstract
Objective: to establish a relationship of the serum levels of the antimicrobial peptides (AMP) cathelicidin (LL-37) and a-defensins (HNP 1-3) to the clinical manifestations of atopic dermatitis (AD) in children. Subjects and methods. The investigation enrolled 70 patients aged 5 months to 17 years with AD. LL-37 and HNP1-3 levels were determined by enzyme immunoassay. Results. The level of HNP 1-3 was found to be higher in children with moderate AD than in those with its mild form. The serum concentration of LL-37 was independent of the severity scoring of atopic (SCORAD) index. However, the level of this peptide was associated with the magnitude of clinical manifestations of the disease. The concentration of LL-37 was increased with an injury over 50% of the body surface; its level rose with the higher intensity of excoriations, lichenification, and pruritus. At the same tone, as the intensity of crusts/oozing lesion increased from mild to moderate, LL-37 rose and drastically decreased at their highest intensity levels. Conclusion. The established correlation between AMP concentration and clinical manifestations of AD suggests that LL-37 and HNP1-3 play a role in the pathogenesis of this disease.
About the Authors
E. I. Ermolaeva
Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
T. V. Vinogradova
Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
A. N. Pampura
Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Boguniewicz M. Leung D. Y. Recent Insights into Atopic Dermatitis and Implications for Management of Infectious Complications. J Allergy Clin Immunol 2010 ; 125: 1: 4—13.
2. OngP.Y., Leung D.Y. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 3: 309-321.
3. OngP. Y., Patel M., Ferdman R.M. et al. Association of staphy-lococcal superantigen-specific IgE with mild and moderate atopic dermatitis. JPediat 2008; 153: 6: 803-806.
4. Цывкина Е.А., Феденко E.C., Будихина A.C., Пинегин Б.В. Оценка уровня антимикробных пептидов (а-дефен-зинов) в лейкоцитах периферической крови больных атопическим дерматитом и пиодермией. Рос аллер-гол журн 2010; 5: 43—47. (Tsyvkina E.A., Fedenko E.S., Budikhina A.S., Pinegin B.V. Assessment of antimicrobial peptides (alpha-defensins) in atopic dermatitis and pyodermia patients blood. Rus Ros allergol zhurn 2010; 5: 43—47.)
5. Selsted M.E., OuelletteA.J. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551—557.
6. Zaiou M., Gallo R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl) 2002; 80: 549-561.
7. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720.
8. Witte M.B., Barbul A. General principles of wound healing. Surg Clin North Am 1997; 77: 3: 509-528.
9. De Y, Chen Q., Schmidt A.P. et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl pep tide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. JExp Med 2000; 192: 1069-1074.
10. Soehnlein O., Kai-Larsen Y, Frithiof R. et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial
11. phagocytosis by human and murine macrophages. J Clin Invest 2008; 118: 10: 3491-3502.
12. Kanda N., Hau C.S., Tada Y. et al. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: relationship between IL-31 and oncostatin M. Allergy 2012; 67: 6: 804-812.
13. Leung T.F., ChingK.W., Kong A.P. et al. Circulating LL-37 is a biomarker for eczema severity in children. J Eur Acad Der-matol Venerol2012; 26: 4: 518-522.
14. Mallbris L., Carlen L., Wei T. et al. Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. Exp Dermatol 2010; 19: 5: 442-449.
15. Ballardini N., Johansson C, Lilja G. et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br J Dermatol 2009; 161: 1: 40-47.
16. HowellM.D., GalloR.L., BoguniewiczM. etal. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341—348.
17. HowellM.D., WollenbergA., GalloR.L. etal. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.
18. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology 1993; 186: 1:23-26.
19. Dillon S.R., Sprecher C, Hammond A. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 7: 752-760.
20. Brogden N.K., Mehalick L., Fischer C.L. et al. The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacol Physiol 2012; 25: 4: 167-181.
Review
For citations:
Ermolaeva E.I., Vinogradova T.V., Pampura A.N. Serum levels of antimicrobial peptides in children with atopic dermatitis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2015;60(4):89-92. (In Russ.)
Views:
512
Email this article 